Add to ORKGCirculating tumor cells have been described in prostate cancer patients at diagnosis and in the metastatic phase but little is known on their role at biochemical PSA recurrence
Introduction. Although 90% of prostate cancer is considered to be localized, 20%–30% of patients wil...
Prostate cancer (PCa) remains a leading cause of death in men, primarily due to ineffective treatmen...
Given the low specificity of the routinely used biomarker prostate-specific antigen, circulating tum...
Background: Circulating tumor cells have been described in prostate cancer patients at diagnosis and...
Prostate cancer is a life-threatening and highly heterogeneous malignancy. In the past decade, circu...
Prostate cancer is a common malignancy with highly molecular heterogeneity responsible for a wide sp...
Prostate cancer is a common malignancy with highly molecular heterogeneity responsible for a wide sp...
The objective of this study was to assess the incidence of circulating tumor cells (CTCs) in prostat...
The aim of this study is to elucidate the clinical significance of prostate-specific membrane antige...
Circulating tumor cells (CTCs) can provide a non-invasive, repeatable snapshot of an individual pati...
International audienceThe aim of this study was to investigate whether the enumeration of circulatin...
Management of patients with prostate cancer is currently based on imperfect clinical, biological, ra...
AbstractOne of the major challenges that clinicians face is in the difficulties of accurately monito...
One of the major challenges that clinicians face is in the difficulties of accurately monitoring dis...
There is an unmet need for reliable biomarkers to predict prostate cancer recurrence after prostatec...
Introduction. Although 90% of prostate cancer is considered to be localized, 20%–30% of patients wil...
Prostate cancer (PCa) remains a leading cause of death in men, primarily due to ineffective treatmen...
Given the low specificity of the routinely used biomarker prostate-specific antigen, circulating tum...
Background: Circulating tumor cells have been described in prostate cancer patients at diagnosis and...
Prostate cancer is a life-threatening and highly heterogeneous malignancy. In the past decade, circu...
Prostate cancer is a common malignancy with highly molecular heterogeneity responsible for a wide sp...
Prostate cancer is a common malignancy with highly molecular heterogeneity responsible for a wide sp...
The objective of this study was to assess the incidence of circulating tumor cells (CTCs) in prostat...
The aim of this study is to elucidate the clinical significance of prostate-specific membrane antige...
Circulating tumor cells (CTCs) can provide a non-invasive, repeatable snapshot of an individual pati...
International audienceThe aim of this study was to investigate whether the enumeration of circulatin...
Management of patients with prostate cancer is currently based on imperfect clinical, biological, ra...
AbstractOne of the major challenges that clinicians face is in the difficulties of accurately monito...
One of the major challenges that clinicians face is in the difficulties of accurately monitoring dis...
There is an unmet need for reliable biomarkers to predict prostate cancer recurrence after prostatec...
Introduction. Although 90% of prostate cancer is considered to be localized, 20%–30% of patients wil...
Prostate cancer (PCa) remains a leading cause of death in men, primarily due to ineffective treatmen...
Given the low specificity of the routinely used biomarker prostate-specific antigen, circulating tum...